We used matched samples of seminal vesicles, prostate transitional zones and prostate cancers from patients operated on for radical prostatectomies and validated their diagnostic performances by demonstrating their ability to discriminate between normal prostate, BPH and cancer tissues, and comparing it with that of known biomarkers of prostate cancers (PCA3, DLX1). This evidence concerns the gene DLX1 and prostate carcinoma.